2021, Clinical Trials, Events and Policy

Harvard Law School Announces the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics

Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. The Project on Psychedelics Law and Regulation (POPLAR). Background. The Project.

Law

Law Policy Research and Development Clinical Trials

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain

Chronic Pain Clinical Trials Research and Development Events

CBD Market Report

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD

CBD Seed-To-Sale Food Access

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development

Research and Development Clinical Trials Events Cannabinoids

Press Release: PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications

Cannabis Law Report

NOVEMBER 19, 2021

19, 2021 /CNW/ – PsyBio Therapeutics Corp. “These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials

Clinical Trials Research and Development Events Safety

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

FEBRUARY 10, 2022

Congress passed the RTT Act in 2018 to give qualifying patients access to investigational drugs outside of a clinical trial setting. Psilocybin successfully completed an FDA-approved Phase 1 clinical trial in 2019, and two companies, COMPASS Pathways and Usona, both currently have Phase 2 trials ongoing.

DEA

DEA Clinical Trials Policy Research and Development

Press Release: Launch of the Psychedelic Access and Research European Alliance – PAREA

Cannabis Law Report

JUNE 14, 2022

There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. PAREA is coming together to address those challenges and provide evidence-based policy recommendations and expertise to the EU policymakers. Ahead of the launch, PAREA Chair Prof.

Access

Access Therapy Clinical Trials Treatment

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

Cannabis Law Report

JULY 29, 2021

VANCOUVER, BC , July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products.

Clinical Trials

Clinical Trials Conditions Packaging Events

Chacruna Institute and Mexican grassroots organizations join forces in a Psilocybin Symposium to discuss the medicalization and commodification of psilocybin in the US

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials

Clinical Trials Events Medicine Therapy

Cannabis Corporate Virus Spreads Across The Pond … Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach

Cannabis Law Report

NOVEMBER 12, 2021

Released 07:00:14 01 November 2021. 01 November 2021. 1 November 2021. of the voting rights of KCP in the Company) that on 1 July 2021, KCP was offered a facility of £1,000,000 by Brown Shipley & Co Limited (“Brown Shipley”) by way of an overdraft (the “Facility”). RNS Number : 8293Q.

Cannabinoids

Cannabinoids Clinical Trials Research and Development Pharmaceutical

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Clinical Trials

Clinical Trials Therapy Research and Development DEA

Chemistree Investee ImmunoFlex™ Completes Clinical Study and Submits US and International Patent Applications

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. SOURCE Chemistree Technology Inc.

Research and Development

Research and Development Clinical Trials Events Treatment

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Cannabis Law Report

NOVEMBER 15, 2021

References: Statement from then FDA Commissioner Scott Gottlieb, MD, and Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. 2021 Aug 26;23:119-127. eCollection 2021 Dec 10. 2021 Aug 26;23:119-127.

Research and Development

Research and Development Therapy Clinical Trials Supply Chain

Sesen Bio Strengthens Senior Leadership Team

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. Hoff and Dr. McLin and four additional new employees between June 1, 2021 and June 14, 2021 pursuant to which an aggregate of up to 1,995,000 shares of Sesen Bio common stock will be purchasable upon vesting. CAMBRIDGE, Mass.–(BUSINESS

Research and Development

Research and Development Treatment Pharmaceutical Patients

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Cannabis Law Report

JULY 25, 2022

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. She was Founder and Executive Producer of the award-winning future-shaping events series, Creative Innovation Global. He has a B.Sc.

Medicine

Medicine Therapy Research and Development Business

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

NOVEMBER 24, 2021

Research into the plant’s chemical compounds has also revealed a rich array of terpenes and flavonoids that may also account for the plant’s therapeutic effects (Kotsirilos and McGregor 2021 ). Australian health authorities advise that cannabis should not be used as a first line of treatment (Kotsirilos and McGregor 2021 ).

Research and Development

Research and Development Medicine Access Media

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

JUNE 4, 2021

This list is focused on those who have had the largest impact for 2021. . Tim Ferriss is Psychedelics Invest’s number one most influential person for 2021 because of his support through his funding, utilization of his multiple massive social outlets, and his continued balanced message about the efficacy and realities of psychedelic medicines.

Research and Development

Research and Development Medicine Treatment Pharmaceutical

NORML 2019 Legislative Report

Cannabis Law Report

DECEMBER 30, 2019

After this historically successful year, we expect to see public and political support continue to increase in 2020 as more and more states implement sensible cannabis regulatory policies. “Never before in American history has marijuana policy advanced in Congress as far or as fast in one year as 2019. Erik Altieri.

Legislation

Legislation Patients Access Banking

Medical Cannabis Brief

Harvard Law School Announces the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Trending Sources

CBD Market Report

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Press Release: PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Press Release: Launch of the Psychedelic Access and Research European Alliance – PAREA

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

Chacruna Institute and Mexican grassroots organizations join forces in a Psilocybin Symposium to discuss the medicalization and commodification of psilocybin in the US

Cannabis Corporate Virus Spreads Across The Pond … Oxford Cannabinoid Technologies’ Shares Fall A Further 20% As Chairman Stands Down Following Market Rule Breach

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Chemistree Investee ImmunoFlex™ Completes Clinical Study and Submits US and International Patent Applications

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Sesen Bio Strengthens Senior Leadership Team

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

NORML 2019 Legislative Report

Stay Connected